Edition:
United Kingdom

Matthias Blamont

Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.

Twitter handle: @jeffmason1

12 Oct 2017

Sanofi boosts vaccines business with 170 million euro investment

VAL-DE-REUIL, France Sanofi on Thursday expressed confidence in the growth of its influenza vaccines after committing to invest 170 million euros to expand its manufacturing facility at Val-de-Reuil in north-western France.

06 Oct 2017

EU should take advantage of drop in migrant influx: OECD'S Gurria

PARIS European Union countries should take advantage of a slowdown in the flow of migrants from Africa and the Middle East to devise a more coherent approach to a crisis that has strained relations between member states, the head of the OECD said on Friday.

26 Sep 2017

Pregnant women still unaware of epilepsy drug risks: EMA hearing

PARIS More than three decades after links emerged between Sanofi's epilepsy drug valproate and birth defects, many pregnant women remain unaware of the risks, patients, doctors and researchers said on Tuesday.

15 Sep 2017

France's Neovacs takes on GSK and AstraZeneca in battle to treat lupus

PARIS French biotech company Neovacs is confident that its experimental drug to treat lupus could grab significant market share from standard treatments of the auto-immune disease, its chief executive said.

31 Jul 2017

Sanofi raises outlook but key eczema drug disappoints investors

PARIS Sanofi raised its 2017 earnings forecast on the back of strong growth in the second quarter but investors were disappointed with sales of key new eczema drug Dupixent, developed with U.S partner Regeneron Pharmaceuticals .

26 Jul 2017

Human Rights Watch - French police use excessive force on Calais migrants

PARIS Human Rights Watch pressed France on Wednesday to end what it described as recurrent police violence against migrants in the northern town of Calais, where hundreds have returned despite the demolition of a sprawling camp once known as "the jungle". | Video

15 Jul 2017

Bastille Day march-past closes Trump's Paris visit

PARIS President Donald Trump watched U.S. and French soldiers march together through the Paris sunshine on Friday in a double celebration marking 100 years since the United States entered World War One and France's annual Bastille Day holiday. | Video

05 Jul 2017

French implant maker Carmat pins hopes on low energy heart

PARIS Artificial heart maker Carmat is hoping a more energy-efficient implant and the appointment of a production chief can help it overcome recent failures at the French firm.

30 Jun 2017

Migrants disillusioned with French asylum process return to Calais

CALAIS, France Somali teenager Abdulaziz Ahmad hunkered down in the sand dunes outside Calais, once again plotting how to reach Britain, eight months after French government bulldozers cleared a sprawling migrants' camp in the northern port town. | Video

22 Jun 2017

Beyond air show, newcomers challenge Airbus-Boeing duopoly

PARIS This year's Paris Air Show was dominated by the annual order battle between Airbus and Boeing , but industry executives said the duopoly will be forced to share the stage at future shows as newcomers from Russia, China and Japan muscle into the passenger plane market.

  • Europe
  • U.S.
  • Asia
  • Sectors
Stock Search
FTSE 100 7,523.23 + 0.19 +0.00%
DAX 12,991.28 -- --%
CAC 40 5,372.38 + 0.00 +0.00%
TR Europe 185.10 -0.44 -0.24%
GBP/USD 1.3193 +0.05%
GBP/EUR 1.1211 +0.10%
EUR/USD 1.1768 -0.14%
Gold 1,277.40 +0.00 +0.00%
Oil 52.05 +0.21 +0.41%
Corn 345.00 +0.50 +0.15%